1	Safety and effectiveness of RBD-specific polyclonal equine F(ab')2 fragments for the
2	treatment of hospitalized patients with severe Covid-19 disease: a retrospective cohort study.
3	Diego H. Farizano Salazar <sup>1¶</sup> , Fernando Achinelli <sup>1¶</sup> , Mariana Colonna <sup>2</sup> , Lucía Perez <sup>3</sup> , Analía
4	A. Giménez <sup>1</sup> , Maria Alejandra Ojeda <sup>1</sup> , Susana N. Miranda Puente <sup>1</sup> , Lía Sánchez Negrette <sup>1</sup> ,
5	Florencia Cañete <sup>1</sup> , Ornela I. Martelotte Ibarra <sup>1</sup> , Santiago Sanguineti, <sup>2</sup> , Linus Spatz <sup>2</sup> ,
6	Fernando A. Goldbaum <sup>2,4,5,6</sup> , Carolina Massa <sup>2</sup> , Marta Rivas <sup>2</sup> , Mariana Pichel <sup>2</sup> , Yanina
7	Hiriart <sup>2,4</sup> , Vanesa Zylberman <sup>2,4</sup> , Sandra Gallego <sup>4,7</sup> , Brenda Konigheim <sup>4,7</sup> , Francisco
8	Fernandez <sup>8</sup> , Matías Deprati <sup>8</sup> , Ian Roubicek <sup>2</sup> , Diego H. Giunta <sup>3,4</sup> , Esteban Nannini <sup>4,9</sup> , Gustavo
9	Lopardo <sup>10,11</sup> and Waldo H. Belloso <sup>3*</sup> , on behalf of EPIC Study Group ^.
10	Affiliations
11	<sup>1.</sup> Hospital de Campaña Escuela Hogar, Corrientes, Corrientes, Argentina
12	<sup>2.</sup> Inmunova S.A., Gral. San Martín, Buenos Aires, Argentina
13	<sup>3.</sup> Department of Research, Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos
14	Aires, Buenos Aires, Argentina.
15	<sup>4.</sup> Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET).
16	<sup>5.</sup> Fundación Instituto Leloir, IIBBA-CONICET. Ciudad Autónoma de Buenos Aires, Argentina.
17	<sup>6.</sup> CRIP - Centro de Rediseño e Ingeniería de Proteínas UNSAM Campus Miguelete. Gral. San
18	Martín, Buenos Aires, Argentina.
19	<sup>7.</sup> Instituto de Virología Dr. José María Vanella, Universidad Nacional de Córdoba, Córdoba,
20	Argentina.
21	<sup>8.</sup> Laboratorio Elea Phoenix S.A., Los Polvorines, Buenos Aires, Argentina
22	<sup>9.</sup> Departamento de Enfermedades Infecciosas, Sanatorio Británico, Rosario, Santa Fe, Argentina.

Lo inospital inalicipal Di. Demardo industa, i formera de Daenos i mes, i igentin	23 <sup>10</sup>	<sup>0.</sup> Ho	spital	Muni	cipal Dr	. Bernardo	Houssay.	, Florida,	Provinci	ia de	<b>Buenos</b>	Aires,	Argentina
---	------------------	------------------	--------	------	----------	------------	----------	------------	----------	-------	---------------	--------	-----------

- 24 <sup>11.</sup> Fundación del Centro de Estudios Infectológicos (FUNCEI), Ciudad Autónoma de Buenos
- 25 Aires, Buenos Aires, Argentina.

- 27 \*Corresponding author email: <u>waldo.belloso@hospitalitaliano.org.ar</u> (WHB). ORCID ID 0000-
- **28** 0002-7048-7841
- 29 ^Additional members of this group are listed in Supplementary Appendix.
- 30 ¶ These authors contributed equally to this work. Author order was determined by mutual
- 31 agreement.

32

### 33 Abstract

Passive immunotherapy has been evaluated as a therapeutic alternative for patients with COVID-34 35 19 disease. Equine polyclonal immunotherapy for COVID-19 (EPIC) showed adequate safety and 36 potential efficacy in a clinical trial setting and obtained emergency use authorization in Argentina. 37 We studied its utility in a real world setting with a larger population. 38 Methods: We conducted a retrospective cohort study at "Hospital de Campaña Escuela-Hogar" in 39 Corrientes, Argentina, to assess safety and effectiveness of EPIC in hospitalized adults with severe 40 COVID-19 pneumonia. Primary endpoints were 28-days all-cause mortality and safety. Mortality 41 and improvement in modified WHO clinical scale at 14 and 21 days were secondary endpoints. 42 Potential confounder adjustment was made by logistic regression weighted by the inverse of the 43 probability of receiving the treatment (IPTW) and doubly robust approach. 44 Results: Clinical records of 395 exposed (EPIC) and 446 non-exposed (Controls) patients admitted 45 between November 2020 and April 2021 were analyzed. Median age was 58 years and 56.8% were males. Mortality at 28 days was 15.7% (EPIC) vs. 21.5% (Control). After IPTW adjustment the 46 47 OR was 0.66 (95 % CI: 0.46 - 0.96), P = 0.03. The effect was more evident in the subgroup who 48 received two EPIC doses (complete treatment, n=379), OR: 0.58 (95% CI 0.39 to 0.85), P=0.005. 49 Overall and serious adverse events were not significantly different between groups. 50 Importance: In this retrospective cohort study, EPIC showed adequate safety and effectiveness in 51 the treatment of hospitalized patients with severe SARS-CoV-2 disease.

52

53

#### 55 1. Introduction

56

From the beginning of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) 57 58 pandemic, different therapeutic approaches have been assessed in randomized controlled trials 59 (RCT) (1). After more than 2 years of pandemic, for hospitalized patients, dexamethasone, 60 remdesivir, tocilizumab, tofacitinib, and baricitinib have shown efficacy in adequately powered 61 clinical trials (2-8). Passive immunotherapy has been widely studied, particularly for patients who 62 have not yet established their specific immune response. To date, convalescent plasma (CP) has 63 shown no effect in the treatment of patients with severe pneumonia. Among ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease, neutralizing 64 antibodies such as bamlanivimab/etesevimab, casirivimab/imdevimab, and 65 monoclonal 66 sotrovimab are also included as therapeutic options likewise the administration of 67 nirmatrelvir/ritonavir, 3-day treatment with remdesivir, and molnupiravir (9-12). However, access to these treatments is certainly limited and the appearance and prevalence of the B.1.1.529 variant 68 (Omicron) has threatened the efficacy of most monoclonal antibodies studied to date (13). 69 70 Effective interventions for the treatment of patients with COVID-19 infection are still urgently 71 needed.

72

73 It has been previously shown that the Receptor Binding Domain (RBD) from the viral spike 74 glycoprotein elicits high titers of neutralizing antibodies (NAbs) against SARS-CoV-2 when used 75 as immunogen in horses (14). Equine polyclonal antibodies (EpAbs) represent a practical and 76 efficient source of NAbs. EpAbs are composed of F(ab')<sub>2</sub> fragments generated by pepsin digestion. 77 We have formerly described the development of an "Equine Polyclonal Immunotherapy for

78 COVID-19" (EPIC) based on equine anti-RBD F(ab')<sub>2</sub> fragments, known as INM005 (15). EPIC 79 showed a very high serum neutralization titer against SARS-CoV-2 and its format, devoid of Fc 80 domains, may prove preferable for its capacity to avoid serum sickness reactions and Fc-triggered 81 side effects (15). The EPIC effect was evaluated in a double-blind, randomized, placebo-controlled 82 trial among hospitalized 241 adults with moderate and severe COVID-19 pneumonia in Argentina 83 (16). Even though the primary endpoint (improvement in at least two categories in WHO ordinal clinical scale at day 28) was not achieved (odds ratio [OR]: 1.61%, 95% confidence interval 84 [95%CI]: 0.71 to 3.63, P=0.34), several secondary endpoints were reached: variation in ordinal 85 86 clinical status during the follow-up period favored EPIC: A) improvement in at least two categories 87 was significantly higher in the EPIC group at days 14 (OR: 0.52, 95% CI: 0.29 to 0.96, P=0.03), and 21 (OR: 0.54, 95% CI: 0.30 to 0.99, P=0.05); B) a significant difference was noted in time to 88 89 improvement in at least two ordinal categories or hospital discharge:  $14.2 (\pm 0.7)$  days in the EPIC group and 16.3 ( $\pm$  0.7) days in the placebo group (hazard ratio: 1.31, 95% CI: 1.0 to 1.74, P=0.05). 90 91 Mortality at day 28 was 6.8% in the EPIC group and 11.4% in the placebo group (OR 0.57, 95% 92 IC: 0.24 to 1.37). Pre-specified subgroup analyses showed a more pronounced effect of the 93 intervention among severe patients lacking antibody response at baseline.

94 With those findings, the Argentinean National Administration of Drugs, Food, and Medical 95 Technology (ANMAT), approved EPIC for the treatment of moderate or severe SARS-CoV-2 hospitalized patients, under special conditions on December 22, 2020 (Provision 9175/20) (17). 96 As required by this approval, the sponsor initiated a prospective nationwide registry of patients 97 98 with SARS-CoV-2 infection treated with EPIC that has already included more than 10,000 99 patients. Since data were collected on an ongoing basis, we decided to conduct a retrospective 100 cohort analysis in a dedicated COVID-19 hospital that used the product regularly, including patients admitted to the same hospital before EPIC was available for historical comparison. 101

- 102 Therefore, the aim of this study was to evaluate the effectiveness and safety of EPIC administration
- 103 in hospitalized patients with severe COVID-19 in a real-world setting.
- 104

# 105 2. Objectives

- 106 The objectives of the study were to compare all-cause mortality at 28 days and the proportion of 107 serious and total adverse events during hospitalization between the exposed and unexposed groups.
- 108

# 109 **3. Study Design and location**

110 A retrospective cohort study was performed including adult patients hospitalized for severe 111 pneumonia with confirmed diagnosis of SARS-CoV-2. The date of hospital admission was 112 considered as the date of admission into the cohort for both groups. All patients were evaluated in 113 a structured manner at days 14, 21 and 28 from inclusion.

All cohort participants were enrolled at the "Hospital de Campaña Escuela-Hogar" (HCEH), a single monovalent site established as a reference center for the diagnosis and treatment of patients with COVID-19 for the whole province in Corrientes city, located in the northeastern region of Argentina. HCEH is a paper-free facility with 723 beds, 300 of which are equipped for critical care.

119

120 The study cohort subjects were divided in two groups: those "exposed to EPIC or EPIC group"
121 that received treatment with purified equine anti-RBD F(ab<sup>^</sup>)<sub>2</sub> fragments (EPIC, CoviFab<sup>®</sup>) and
122 those "Non-exposed or Control group" that never received that intervention.

123 Following ANMAT's approval, issued on January 27th, 2021, EPIC was adopted as standard of 124 care for patients with COVID-19 within the HCEH. Therefore, we selected that date to divide the 125 cohort groups in exposed cases onward from that date to April 17th, 2021, and non-exposed cohort 126 group backward from January 21st, 2021 to November 25th, 2020 in order to increase 127 comparability, and also to avoid the possibility of a learning curve period for the treatment of 128 patients with COVID-19 close to the beginning of operations at HCEH. 129 The study protocol was approved by the Institutional Review Boards from both the HCEH and the 130 "Hospital Italiano" of Buenos Aires city, Argentina. The protocol was registered in 131 ClinicalTrials.gov with the number NCT04954235. All data extracted from the electronic clinical 132 records was anonymized at completion of the structured study forms and remained in that way for 133 the whole analysis process. 134 135 4. Methods

#### 136 **Population**

Adult patients with confirmed diagnosis of SARS-CoV-2 severe pneumonia hospitalized at HCEH
between November 25th, 2020 until April 17th, 2021, meeting the study selection criteria.

139

#### 140 Exposure

Patients were labeled as exposed (EPIC) if they received at least one of 2 doses of 4 mg/Kg of EPIC in intravenous infusion of 100 ml of saline over a period of fifty minutes (with an interval of 48 hours between doses). The control group was recruited among hospitalized patients that did not receive that intervention because they were hospitalized before EPIC was available.

145

# 146 Selection criteria

Patients were included in the study if had between 18 and 79 years old, COVID-19 diagnosis confirmed by SARS-CoV-2 antigen test or reverse-transcriptase-polymerase-chain reaction (qRT-PCR -GeneDX Co, Ltd or similar) or positive anti SARS-CoV-2 IgM antibodies, had severe disease defined as: respiratory rate of more than 30/min, or oxygen saturation <94% on room air at sea level, or a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, or lung compromise of more than 50%.</p>

Exclusion criteria were: SARS-CoV-2 disease other than severe (asymptomatic, mild, moderate or critical), pregnant women or during lactation period, patients already admitted to intensive care unit (ICU), confirmation of microbiological cause of pneumonia other than SARS-CoV-2, patients with therapeutic limitation or patients with history of anaphylaxis or severe allergic reaction to equine sera or to contact or exposure to horse proteins. A detailed description of the disease severity categories is provided in the Supplementary Appendix.

159

# 160 Data collection

Data capture was performed through ACTide-eCRF, an electronic case report form based on a multi-platform interface that was previously reviewed by ANMAT and used for the registry of all patients receiving EPIC in accordance with Provision 4622/12 regarding "Authorization under Special Conditions". This platform was in full agreement with current regulations regarding validation, compliance and certification of computing systems (e.g., CFR 21 Part 11, EU GMP

Annex 11, GAMP5, GDPR and HIPAA). A specific allowance system was implemented for thestudy based upon personnel roles.

168 Patients from the exposed group provided written informed consent for the administration of EPIC.

169 A team of physicians trained on data collection retrieved the required information for each selected

170 patient at baseline, and at days 14, 21, and 28 using specifically designed structured forms.

Patients from the non-exposed group were identified through a systematic review of the electronic
clinical records from HCEH, and their data was retrieved by the same data collection team using
the same structured forms.

#### 174 Variables

175 Structured forms used for both cohort groups included demographic variables (age in years, gender 176 at birth and body mass index-BMI), comorbidities (hypertension, diabetes, obesity, cancer, chronic 177 obstructive pulmonary disease, chronic hepatic insufficiency, chronic renal insufficiency and 178 cardiovascular disease), use of convalescent plasma since 30 days prior to hospital admission, Charlson Score as a measure of comorbidity prognosis, clinical variables at baseline (diagnostic 179 180 method, time from symptoms onset, respiratory rate, oxygen saturation, PaO2/FiO2, requirement of supplementary oxygen and National Early Warning Score-NEWS), and variables related to 181 182 clinical outcomes including WHO-modified 6-points ordinal clinical scale (18-20). Further details 183 of variable operationalization are provided in the Supplementary Appendix.

184

#### 185 Outcomes

Primary outcome was all-cause mortality between cohort groups at day 28 since cohort admission.
Secondary outcomes included mortality between groups at day 14 and 21 since cohort admission,
WHO-modified 6-points ordinal clinical scale (1 non-hospitalized with full restitution of physical

functions, 2 non hospitalized without complete restitution of physical functions, 3 hospitalized without oxygen requirement, 4 hospitalized requiring supplemental oxygen, 5 invasive ventilatory support and 6 death) measured at days 14, 21 and 28, the proportion of patients discharged from hospital at same intervals, time (in days) between cohort admission and hospital discharge, proportion of patients transferred to ICU, time (in days) since cohort admission to discharge from ICU, proportion of patients requiring mechanical ventilation, and time (in days) since cohort admission to start of mechanical ventilation (21).

Safety outcomes included the percentage of patients suffering from any type and/or serious adverse
events. For all adverse events the following data was captured: start and end date, severity,
causality assessment, and treatment. The Adverse Event table was organized according to the
MedDRA SOC (System Organ Class).

200

#### 201 Sample size

Based upon a prior experience with the use of EPIC in the context of a clinical trial, an estimated mortality of 24% for the "non-exposed" patients was assumed. As such, a reduction in mortality of at least 8% (e.g., 16% for exposed and 24% for non-exposed patients) was considered clinically meaningful. With these assumptions, a minimal inclusion of 392 exposed and 392 non-exposed patients (784 patients in total) was required for a two-tailed test with an  $\alpha$  error of 5% and 80% of statistical power. We aimed to include a sample size of 800 patients (1:1 ratio with 400 in each cohort group).

#### 209

### 210 Statistical methods and bias management

We used absolute and relative frequencies (percentages) to describe categorical variables, mean and standard deviation (SD), or median and interquartile range (IQR: 25th centile and 75th centile) to describe quantitative variables. We used Chi-square test or Fisher's exact test for categorical variables and T test or Wilcoxon rank sum test to compare the exposed and non-exposed characteristics.

Effectiveness estimates for treatment might be confounded by indication as a result of treatment decisions based on observed characteristics. Given the observational nature of the study, we use an inverse probability of treatment weighting (IPTW) approach to estimate the causal association -also referred as average treatment effect- of EPIC considering potential confounders (22). This method, which is an extension of the propensity score, is particularly helpful in the estimation of causal associations when a randomized clinical trial is unfeasible. The IPTW approach generates weighted cohorts removing the differences in relevant observed confounders (23).

223 We estimated the propensity score (PS) of EPIC exposure using a logistic regression model with 224 EPIC exposure as dependent variable and the following potential predictors of treatment: gender 225 at birth, age, clinical parameters at cohort admission (respiratory rate, heart rate, body temperature, 226 oxygen saturation), requirement of supplementary oxygen or non-invasive ventilation, Charlson's 227 Score, National Early Warning Score (NEWS), time from symptoms onset, prior use of angiotensin 228 converting enzyme inhibitors, non-steroidal antiinflammatory agents, corticosteroids, heparin, 229 immunosuppressants, ivermectin or statins; presence and number of comorbidities: obesity, 230 cardiovascular disease, stroke, hemiplegia, hypertension, chronic lung disease, chronic renal

disease, dementia, peptic ulcer, diabetes with or without target organ damage, solid organ tumor
or leukemia. With this propensity score we calculated the stabilized IPTW. The weights were
truncated at percentile 1% and 99% to avoid extreme figures.

234 We used Cox's proportional hazards regression model to estimate the hazard ratio (HR) for 235 calculation of the primary endpoint. We also informed the OR between cohort groups calculated 236 with a logistic regression model. The effect of EPIC on the distribution of the modified WHO-237 clinical ordinal scale at 14, 21 and 28 days was accessed with an ordinal logistic regression model 238 and presented as proportional Odds Ratio using Brant test (parallel regression assumption test) 239 (pOR) (24-28). We used conventional logistic regression models to estimate the Odds Ratio (OR) 240 of the exposure to EPIC on the comparison of the proportion of hospital discharge at 14, 21 and 241 28 days, and the proportion of adverse effects. We use Fine and Gray's regression model to 242 estimate the subhazard ratio (sHR) for the association between EPIC and the requirement of 243 mechanical ventilation using death as a competing event (29).

244 For the primary analysis we estimated the causal association between EPIC exposure and primary 245 or secondary outcomes using regression models weighted by the inverse of the probability of 246 receiving treatment, considering EPIC exposure as the independent variable (IPTW). In addition, 247 we presented the data with a conventional adjustment for potential confounders either with the raw 248 data and with the IPTW-treated data, in a doubly robust approach. Variables included in this 249 adjustment included: gender at birth, age, respiratory rate at cohort entry, oxygen saturation, 250 requirement of supplementary oxygen or non-invasive ventilation, Charlson's Score, NEWS, time 251 from symptoms onset, obesity, cancer and chronic lung disease. We presented all data with 95% 252 confidence interval (95% CI). To assess the balance in potential confounders between exposure 253 groups, we used standardized differences before and after IPTW adjusting. We considered

balanced covariates all those who had standardized differences lower than 10% after IPTW
adjusting (30). We presented the balance diagnosis of IPTW in a Love plot according to Austin
and Stuart (31).

We performed predefined subgroup analysis of primary outcomes considering gender at birth, age category groups (less than 65, or between 65 and 79 years old), time from symptoms initiation (less than 3 days, between 3 and 5, between 5 and 10 or more than 10), obesity, presence and number of main comorbidities (immunosuppression, diabetes, hypertension, cardiovascular disease) and number of doses of EPIC (one versus two). We also performed a sensitivity analysis considering the patients from the "Control" group that did or did not receive convalescent plasma.

The detailed statistical analysis plan is provided in the Supplementary Appendix. All tests were
two-sided, and a P value <0.05 was considered statistically significant. All statistical analysis was</li>
performed using STATA statistical software version 15.1 MP - Parallel Edition (Copyright 19852017 StataCorp LLC - StataCorp. 4905 Lakeway Drive, College Station, Texas 77845 USA).

267

#### 268 **5. Results**

269 Patients

Following protocol's approval, data collection from both cohort groups started on May 27th, 2021.
During the pre-specified -backward and onward- collection times, from 1352 clinical records
reviewed, 395 patients met the inclusion criteria for the EPIC group and 446 patients were included
in the Control group, for a total cohort of 841 patients. Fig. 1 depicts the complete patient
disposition.

275 Median age was 58 years old (interquartile range 48 to 69), and 57.9% were male. Body mass 13

index was 31.1 (interquartile range 28.1 to 36) in the EPIC group and 28.6 (interquartile range 26
to 33.2) in the Control group, with 117 and 235 patients in the EPIC group, and 194 and 176
patients in the Control group reaching the standard definition for overweight and obesity,
respectively. Standard and modified Charlson's scores at cohort entry were similar between
groups.

At cohort admission the median time from symptoms initiation was 7 days (interquartile range 5 to 8) for the EPIC group and 6 days (interquartile range 3 to 9) for the Control group.

While most patients had at least one identified comorbidity, significantly more patients had no comorbidities in the Control group than in the EPIC Group: 67 (15%) vs. 36 (9.1%), respectively, p=0.009. Obesity -235 patients (59.5%) and 176 (39.5%), P=<0.001- along with hypertension -228 (57.7%) and 242 (54.3%)-, and diabetes -111 (28.1%) and 110 (24.7%) in EPIC and Control groups, respectively, were the most prevalent coexisting conditions.

No statistically significant differences were found in body temperature, and heart and respiratory
rates between cohort groups, whereas oxygen saturation at cohort entry was 92% (interquartile
range 89 to 93%) for EPIC group and 90.5% (interquartile range 88 to 93) for the Control group,
(P<0.0001). Accordingly, the modified NEWS score at cohort admission was significantly</li>
different between groups (P=0.006).

A total of 46.3% of the cohort patients (179 in EPIC group and 211 in the Control group) were receiving antihypertensive drug treatment (angiotensin converting enzyme inhibitors and angiotensin receptor blockers) at admission, while a minority of patients received other drugs as immunosuppressants, statins, anticoagulants, ivermectin, and corticosteroids, none of them being statistically different between groups. A more detailed description of the baseline patient conditions and comparison between cohort groups is shown in Table 1.

During the cohort follow up time 395 patients (100%) in the EPIC group and 406 patients (91%) in the Control group received corticosteroids, 392 (99%) and 410 (91.9%) received heparin, 274 (69.4%) and 321 (72%) received antibiotics, respectively, while 317 (71.19%) in the Control group received convalescent plasma (exclusion criterion for EPIC group). A complete description of concomitant treatment interventions during cohort follow up is shown in Table 2.

304

305 Intervention

No patients in the Control group received polyclonal specific hyperimmune serum against SARS-CoV-2. All three hundred and ninety-five patients in the EPIC group received one dose of hyperimmune serum and 379 patients (96%) completed the two-dose pre-specified treatment. Reasons for failure in completing the intervention included admission to UCI and staff refusal to continue treatment (10 cases), adverse events (2 cases), patient voluntary discharge from Hospital (1 case), patient refusal (1 case) and other reasons (2 cases).

312

313 Primary outcome

314 Overall mortality at 28 days was significantly lower for patients in the EPIC group than for patients

in the Control group. The OR was 0.66 (95% CI 0.46 to 0.96 p=0.03) and the HR for the IPTW-

adjusted data was 0.70 (95% CI 0.50-0.98 p=0.037). The doubly robust approaches provided

317 similar results (Table 3, Fig. 2).

318

319 Secondary outcomes

320 Overall mortality at 21 and 14 days were not statistically different between cohort groups (OR for

the IPTW-adjusted data and for the doubly robust approach were 0.72 [95% CI 0.49 to 1.06] and
0.73 [95% CI 0.48 to 1.10], and 0.81 [95% CI 0.52 to 1.26] and 0.86 [95% CI 0.53 to 1.39],
respectively.

WHO-modified 6 points ordinal clinical scale results were significantly better for the EPIC group than for the Control group at 14 days (proportional OR 0.71 [95% CI 0.53 to 0.95] for IPTWadjusted and proportional OR 0.68 [95% CI 0.50 to 0.94] for the doubly robust approach), while no significant differences were noted at days 21 and 28 between groups (Table 3, Fig. S2).

Hospital discharge rate was also significantly higher for the EPIC group than for the Control group
at 14 days (OR 1.46 [95% CI 1.07 to 1.98] for IPTW-adjusted and OR 1.49 [95% CI 1.07 to 2.09]
for the doubly robust approach), while no differences were found between cohort groups at days
21 and 28.

No significant differences were found between groups in median time to hospital discharge, proportion of patients requiring admission to ICU, median time until discharge from ICU, proportion of patients requiring mechanical ventilation or median time until initiation of mechanical ventilation. Complete results for secondary outcomes are shown in Table S2 and Fig. S3, S4 and S5.

337

338 Safety outcomes

339 Safety outcomes included the percentage of patients with any type and/or serious adverse events,
340 and the comparison of total and serious adverse events (AE) during hospital admission between
341 EPIC and Control groups.

342 EPIC was overall well tolerated, 98 patients (24.8%) in the EPIC group and 121 (27.1%) in the

Control group had at least one adverse event, being respiratory, thoracic and mediastinal disorders (20.3% in EPIC group and 26% in Control group), and administration site complications (11.6% in EPIC and 9.6% in Control group) the most frequently observed, with no statistical difference between cohort groups. Two patients out of 395 in the EPIC group did not receive the second dose of the study product due to adverse events, i.e., a cutaneous rash and a hypotension event, both of which resolved satisfactorily.

349

Serious adverse events (SAE) were frequently observed among cohort patients, probably due to
the population characteristics, although no significant difference between groups was observed.
SAE occurred in 78 patients (19.7%) in the EPIC group and in 106 (23.8%) in the Control group.
Six AEs were considered probable or possibly related to EPIC.

No anaphylaxis event was reported, and no death episodes were considered by the investigators to
be related to the investigational product. Table 4 and Table S4 show a more detailed description
of the AE between cohort groups.

357

#### 358 6. Discussion

359

In this retrospective study, the administration of at least one infusion of EPIC for hospitalized patients with severe COVID-19 significantly reduced the 28-day mortality by 34% (15.7% vs 21.5%) compared with a group of patients treated at the same hospital before EPIC was available. This effect was more evident in patients receiving the two infusions of the investigational product (28-day mortality of 14% vs 21.5%), resulting in 13 patients needed to treat in order to prevent one additional death. During the trial, EPIC-related adverse events were minimal and non-serious.

Currently, no virus directed therapy has shown to reduce mortality among hospitalized patients with severe SARS-CoV-2 infection; only agents decreasing the inflammatory response such as dexamethasone, baricitinib (or tofacitinib), and tocilizumab (or sarilumab) were able to reduce the mortality rate in this setting (3, 7, 32, 33).

Administration of different types of immunotherapy has been explored as a therapeutic approach for patients with severe COVID-19 disease with variable results. Recent data from three randomized clinical trials studies comparing anti-spike mAbs (bamlanivimab, VIR-7831, and the combination BRII-196/198) with placebo were terminated due futility after randomization of 314, 344 and 343 patients, respectively (34, 35).

However and as expected, most of the clinical benefits obtained from passive immunotherapies might be observed in patients lacking specific anti-SAR-CoV-2 antibodies due to a delayed response or to immunocompromise. In this regard, among patients randomized to placebo in the Recovery trial, the 28-day mortality was significantly higher in the baseline seronegative group (30%) than in the seropositive one (15%). Even more, in those lacking specific antibodies at baseline, the mortality was 24% and 30% in the mAbs combination and placebo arm, respectively (rate ratio 0.80) (36).

The positive impact of polyclonal equine anti-RBD  $F(ab')_2$  fragments described here might follow the findings reported in the Recovery clinical trial. Given the observational nature of this study, baseline anti-SARS-CoV-2 immune status could not be determined. Lacking this information forbidden us to identify a subgroup of seronegative patients who might have benefited the most from this type of therapy. Remarkably, a significant effect on the primary outcome was observed for the entire population while in the Recovery trial that enrolled 9785 patients, a decrease in the 28-day mortality was seen only in those with no baseline antibodies (36).

389 It should be noted that, in a double-blind randomized clinical trial, the treatment of EPIC was 390 associated with a 45% non-statistically significant decrease in mortality among the subgroup of 391 severe patients hospitalized with COVID-19 disease (16) (13.6% in the EPIC group vs 24.5% in 392 the placebo group, OR: 0.52). It is likely that this outcome did not reach statically significance 393 because of the low number of severe patients enrolled. Moreover, EPIC showed a statistically 394 significant difference in the WHO-modified 6 points ordinal clinical scale at 14 days. This was correlated with also a statistically significant difference at hospital discharge rate at 14 days. These 395 effects were not observed neither at day 21 nor at day 28 (16). 396

397 In regard to safety results, these findings were as expected in patients with COVID-19 severe 398 disease as adverse events observed were mainly related to disease progression and complications 399 such as multiorgan failure and in similar proportions in both groups. EPIC showed a good safety 400 profile similar to the one observed in the RCT. All related events were treated and resolved 401 satisfactorily within the same date. In this real-world experience only in 2 of the 395 patients 402 treated with EPIC the second dose was not infused due to adverse events during the first dose. 403 These findings are aligned with the adverse event reporting rate observed through the Argentinean 404 EPIC registry of 10.728 patients where hypersensitivity events were reported in a frequency of 1-405 2% through the period December 2020 and August 2021 (37).

The main limitation of the study is the non-randomized design; however, data collection included structured forms applied for subjects enrolled in both cohort groups and at the same Hospital. Even more, all hospitalized subjects with COVID-19 were evaluated and enrolled in the study in a consecutive manner. Another existing limitation is that patients were included in one clinical site, missing the generalizability observed in multicenter trials. Of note, the results shown here should not be extrapolated to the vaccinated population nor to those with prior COVID-19 disease since

412 only one participant had received a COVID-19 vaccine and a history of SARS-CoV-2 infection413 was an exclusion criterion.

414 Although this was not fully studied, it can be speculated that most of the patients enrolled in this 415 study were probably infected with the Gamma or P.1 variant due to the epidemiological situation 416 of Argentina at the time of study. Nevertheless, being of polyclonal nature, EPIC has a broader 417 recognition of epitopes on RBD Spike protein than mAbs, making this immunotherapy more robust 418 against viral scape mutations. Interestingly, EPIC showed high neutralizing activity against 419 Gamma and Delta variants of concern and was also capable of neutralizing Omicron, although 420 with less efficiency (Gallego S. et al., unpublished data). Therefore, the clinical benefit observed 421 in this study could be extrapolated to patients infected with any of the above-mentioned variants 422 of concern.

423

# 424 7. Conclusion

After proper adjustment by confounders, this retrospective study in a real-world setting suggests a
favorable effect of EPIC on the 28-day mortality rate in patients with severe SARS-CoV-2
infection admitted to a monovalent hospital site in Argentina, with an adequate safety profile.

428

# 429 Funding

430 Funded by Inmunova SA. and Laboratorio Elea Phoenix S.A.

431

# 432 7. References

4331.Thoguluva Chandrasekar V, Venkatesalu B, Patel HK, Spadaccini M, Manteuffel J, Ramesh20

- 434 M. 2021. Systematic review and meta-analysis of effectiveness of treatment options against
  435 SARS-CoV-2 infection. J Med Virol 93:775–785.
- 436 2. Sterne JAC, Murthy S, Diaz J V., Slutsky AS, Villar J, Angus DC, Annane D, Azevedo
- 437 LCP, Berwanger O, Cavalcanti AB, Dequin P-F, Du B, Emberson J, Fisher D, Giraudeau
- 438 B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Jüni
- 439 P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F,
- 440 Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall
- 441 JC. 2020. Association Between Administration of Systemic Corticosteroids and Mortality
- 442 Among Critically Ill Patients With COVID-19. JAMA 324:1330.
- 443 3. RECOVERY Collaborative Group. 2021. Dexamethasone in Hospitalized Patients with
  444 Covid-19. N Engl J Med 384:693–704.
- 445 4. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu
- 446 HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V,
- 447 Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC,
- 448 Ohmagari N, Oh M, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar
- 449 RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green
- 450 M, Makowski M, Osinusi A, Nayak S, Lane HC. 2020. Remdesivir for the Treatment of
- 451 Covid-19 Final Report. N Engl J Med 383:1813–1826.
- 452 5. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M,
- 453 Ahn M-Y, Nahass RG, Chen Y-S, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C,
- 454 Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima
- 455 KT, Diaz G, Subramanian A. 2020. Remdesivir for 5 or 10 Days in Patients with Severe
- 456 Covid-19. N Engl J Med 383:1827–1837.
- Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu
   21

$\pi_{00}$ $\pi$
--

- 459 OTY, Bernasconi E, Le Turnier P, Chang S-C, SenGupta D, Hyland RH, Osinusi AO, Cao
- 460 H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal
- 461 AJ, Huhn G, Marty FM. 2020. Effect of Remdesivir vs Standard Care on Clinical Status at
- 462 11 Days in Patients With Moderate COVID-19. JAMA 324:1048.
- 463 7. RECOVERY Collaborative Group. 2021. Tocilizumab in patients admitted to hospital with
  464 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet
  465 (London, England) 397:1637–1645.
- 466 8. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC,
- 467 Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El
- 468 Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF,
- 469 Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N,
- 470 Ahuja N, Frank M, Oh M-D, Kim E-S, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor
- 471 BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN,
- 472 Watanabe M, Billings J, Elie M-C, Davey RT, Burgess TH, Ferreira J, Green M, Makowski
- 473 M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU,
- 474 Dodd LE, Beigel JH, ACTT-2 Study Group Members. 2021. Baricitinib plus Remdesivir
- 475 for Hospitalized Adults with Covid-19. N Engl J Med 384:795–807.
- ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, Barkauskas CE,
   Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC,
   Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker J V, Jensen J-U, Gardner EM,
   Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC,
   Davey VJ, Goodman A, Higgs ES, Murray DD, Murray TA, Paredes R, Parmar MKB,
- 481 Phillips AN, Reilly C, Sharma S, Dewar RL, Teitelbaum M, Wentworth D, Cao H, Klekotka

482		P, Babiker AG, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD.
483		2021. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N
484		Engl J Med 384:905–914.
485	10.	Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla
486		B, Stosor V, Shawa I, Adams AC, Van Naarden J, Custer KL, Shen L, Durante M, Oakley
487		G, Schade AE, Sabo J, Patel DR, Klekotka P, Skovronsky DM. 2021. SARS-CoV-2
488		Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 384:229-
489		237.
490	11.	Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y,
491		Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT,
492		Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva
493		Y, Graber X, Kowal B, DiCioccio T, Stahl N, Lipsich L, Braunstein N, Herman G,
494		Yancopoulos GD, Trial Investigators. 2021. REGN-COV2, a Neutralizing Antibody
495		Cocktail, in Outpatients with Covid-19. N Engl J Med 384:238-251.
496	12.	Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis
497		J, Zheng H, Scott N, Cathcart AL, Hebner CM, Sager J, Mogalian E, Tipple C, Peppercorn
498		A, Alexander E, Pang PS, Free A, Brinson C, Aldinger M, Shapiro AE. 2021. Early
499		Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J
500		Med 385:1941–1950.
501	13.	VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE, Purcell LA, Kawaoka Y,
502		Corti D, Fremont DH, Diamond MS. 2022. An infectious SARS-CoV-2 B.1.1.529 Omicron
503		virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med
504		https://doi.org/10.1038/s41591-021-01678-y.

505 14. Boyer L, Degan J, Ruha A-M, Mallie J, Mangin E, Alagón A. 2013. Safety of intravenous
 23

equine F(ab')2: Insights following clinical trials involving 1534 recipients of scorpion 506 507 antivenom. Toxicon 76:386–393.

- 508 15. Zylberman V, Sanguineti S, Pontoriero A V, Higa S V, Cerutti ML, Morrone Seijo SM,
- 509 Pardo R, Muñoz L, Acuña Intrieri ME, Alzogaray VA, Avaro MM, Benedetti E, Berguer
- 510 PM, Bocanera L, Bukata L, Bustelo MS, Campos AM, Colonna M, Correa E, Cragnaz L,
- 511 Dattero ME, Dellafiore M, Foscaldi S, González J V, Guerra LL, Klinke S, Labanda MS,
- Lauché C, López JC, Martínez AM, Otero LH, Peyric EH, Ponziani PF, Ramondino R, 512
- 513 Rinaldi J, Rodríguez S, Russo JE, Russo ML, Saavedra SL, Seigelchifer M, Sosa S, Vilariño
- 514 C, López Biscayart P, Corley E, Spatz L, Baumeister EG, Goldbaum FA. 2020. 515 Development of a hyperimmune equine serum therapy for COVID-19 in Argentina. 516
- Medicina (B Aires) 80 Suppl 3:1-6.
- 517 16. Lopardo G, Belloso WH, Nannini E, Colonna M, Sanguineti S, Zylberman V, Muñoz L,
- 518 Dobarro M, Lebersztein G, Farina J, Vidiella G, Bertetti A, Crudo F, Alzogaray MF,
- 519 Barcelona L, Teijeiro R, Lambert S, Scublinsky D, Iacono M, Stanek V, Solari R, Cruz P,
- 520 Casas MM, Abusamra L, Luciardi HL, Cremona A, Caruso D, de Miguel B, Lloret SP,
- 521 Millán S, Kilstein Y, Pereiro A, Sued O, Cahn P, Spatz L, Goldbaum F. 2021. RBD-specific
- 522 polyclonal F(ab)2 fragments of equine antibodies in patients with moderate to severe
- 523 COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive
- 524 phase 2/3 clinical trial. EClinicalMedicine 34:100843.
- 525 17. Argentinean National Administration of Drugs, Food, and Medical Technology
- 526 (ANMAT). 2012. Disposition 4622.
- 527 http://www.anmat.gov.ar/boletin\_anmat/agosto\_2012/Dispo\_4622-12.pdf.
- 528 18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying
- prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 529

**530** 40:373–83.

- 531 19. Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, Spazzafumo L, Mancinelli
  532 L, Espinosa E, Rappelli A, Dessì-Fulgheri P. 2008. A Manual of Guidelines to Score the
  533 Modified Cumulative Illness Rating Scale and Its Validation in Acute Hospitalized Elderly
  534 Patients. J Am Geriatr Soc 56:1926–1931.
- 535 20. Royal College of Physicians. 2017. https://www.rcplondon.ac.uk/projects/outputs/national536 early-warning-score-news-2.
- 537 21. Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, Baillie K, Bauer M,
- 538Berry S, Blackwood B, Bonten M, Bozza F, Brunkhorst F, Cheng A, Clarke M, Dat VQ, de
- Jong M, Denholm J, Derde L, Dunning J, Feng X, Fletcher T, Foster N, Fowler R, Gobat
- 540 N, Gomersall C, Gordon A, Glueck T, Harhay M, Hodgson C, Horby P, Kim Y, Kojan R,
- 541 Kumar B, Laffey J, Malvey D, Martin-Loeches I, McArthur C, McAuley D, McBride S,
- 542 McGuinness S, Merson L, Morpeth S, Needham D, Netea M, Oh M-D, Phyu S, Piva S, Qiu
- 543 R, Salisu-Kabara H, Shi L, Shimizu N, Sinclair J, Tong S, Turgeon A, Uyeki T, van de
- 544 Veerdonk F, Webb S, Williamson P, Wolf T, Zhang J. 2020. A minimal common outcome
- 545 measure set for COVID-19 clinical research. Lancet Infect Dis 20:e192–e197.
- 546 22. Katz MH. 2011. Multivariate analysis: A Practical Guide for Clinicians and Public Health
  547 Researchers. Cambridge University Press.
- 548 23. Matschinger H, Heider D, König H-H. 2020. A Comparison of Matching and Weighting
  549 Methods for Causal Inference Based on Routine Health Insurance Data, or: What to do If
  550 an RCT is Impossible. Das Gesundheitswes 82:S139–S150.
- 551 24. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. 1996. A simulation study of
  552 the number of events per variable in logistic regression analysis. J Clin Epidemiol 49:1373–
  553 1379.

25. McCullagh P. 1980. Regression Models for Ordinal Data. J R Stat Soc Ser B 42:109–127.

- 555 26. Williams R. 2016. Understanding and interpreting generalized ordered logit models. J Math
  556 Sociol 40:7–20.
- 557 27. University of California Los Angeles. Ordered logistic regression | Stata annotated output.

https://stats.idre.ucla.edu/stata/output/ordered-logistic-regression/. Retrieved 17 July 2021.

- 559 28. Brant R. 1990. Assessing Proportionality in the Proportional Odds Model for Ordinal
  560 Logistic Regression. Biometrics 46:1171.
- 561 29. Fine JP, Gray RJ. 1999. A Proportional Hazards Model for the Subdistribution of a
  562 Competing Risk. J Am Stat Assoc 94:496–509.
- 30. Ho DE, Imai K, King G, Stuart EA. 2007. Matching as Nonparametric Preprocessing for
  Reducing Model Dependence in Parametric Causal Inference. Polit Anal 15:199–236.
- Austin PC, Stuart EA. 2015. Moving towards best practice when using inverse probability
  of treatment weighting (IPTW) using the propensity score to estimate causal treatment
  effects in observational studies. Stat Med 34:3661–3679.
- 32. REMAP-CAP Investigators. 2021. Interleukin-6 Receptor Antagonists in Critically III
  Patients with Covid-19. N Engl J Med 384:1491–1502.
- 570 33. Marconi VC, Ramanan A V, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB,

571 Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A,

572 Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW, Ahn M-Y, Akasbi M,

- 573 Alatorre-Alexander J, Altclas JD, Ariel F, Ariza HA, Atkar C, Bertetti A, Bhattacharya M,
- 574 Briones ML, Budhraja A, Burza A, Camacho Ortiz A, Caricchio R, Casas M, Cevoli Recio
- 575 V, Choi WS, Cohen E, Comulada-Rivera A, Cook P, Cornejo Juarez DP, Daniel C, Degrecci
- 576 Relvas LF, Dominguez Cherit JG, Ellerin T, Enikeev D, Erico Tanni Minamoto S, Estrada
- 577 V, Fiss E, Furuichi M, Giovanni Luz K, Goldman JD, Gonzalez O, Gordeev I, Gruenewald

578		T, Hamamoto Sato VA, Heo EY, Heo JY, Hermida M, Hirai Y, Hutchinson D, Iastrebner
579		C, Ioachimescu O, Jain M, Juliani Souza Lima MP, Khan A, Kremer AE, Lawrie T,
580		MacElwee M, Madhani-Lovely F, Malhotra V, Martínez Resendez MF, McKinnell J,
581		Milligan P, Minelli C, Moran Rodriguez MA, Parody ML, Paulin P, Pellegrini R de C, Pemu
582		P, Procopio Carvalho AC, Puoti M, Purow J, Ramesh M, Rea Neto A, Rea Neto A, Robinson
583		P, Rodrigues C, Rojas Velasco G, Saraiva JFK, Scheinberg M, Schreiber S, Scublinsky D,
584		Sevciovic Grumach A, Shawa I, Simon Campos J, Sofat N, Som M, Spinner CD, Sprinz E,
585		Stienecker R, Suarez J, Tachikawa N, Tahir H, Tiffany B, Vishnevsky A, Westheimer
586		Cavalcante A, Zirpe K. 2021. Efficacy and safety of baricitinib for the treatment of
587		hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind,
588		parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 9:1407–1418.
589	34.	ACTIV-3/TICO LY-CoV555 Study Group. 2021. A Neutralizing Monoclonal Antibody
590		for Hospitalized Patients with Covid-19. N Engl J Med 384:905–914.
591	35.	National Institute of Health. 2021. https://www.nih.gov/news-events/news-releases/nih-
592		sponsored-activ-3-clinical-trial-closes-enrollment-into-two-sub-studies.
593	36.	RECOVERY Collaborative Group. 2022. Casirivimab and imdevimab in patients admitted
594		to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform
595		trial. Lancet (London, England) 399:665-676.
596	37.	Argentinean National Administration of Drugs, Food, and Medical Technology (ANMAT).
597		2022. https://www.argentina.gob.ar/sites/default/files/dispo_0951-22_covifab_reins.pdf.
598		

599

### 601 Tables and Figures



§ [guida]L.Simiky poi bails 0404830030 (illusiolismi)

- 605 FIG 1. Cohort patient disposition

- . . .

#### 613

	EPIC	Control	P value					
	(N=395)	(N=446)						
Characteristics								
Age, years#	57 (48-67)	59 (48-69)	0.1881†					
Male sex	60.3 (238)	55.8 (249)	0.195					
BMI**	BMI**							
Median (Interquartile range)#	31.1 (28 - 36)	28.6 (26-33.2)	<0.0001†					
Normal	10.9 (43)	12.6 (56)						
Overweight	29.6 (117)	43.5 (194)	<0.001					
Obesity	59.5 (235)	39.5 (176)						
Coexisting conditions								
Charlson score	0 (0 - 2)	0 (0 - 2)	0.9982†					
Number of comorbidities#	2 (1 - 3)	1 (1 - 3)	0.0003†					
None	9.1 (36)	15.0 (67)	0.009					
Hypertension	57.7 (228)	54,3 (242)	0.313					
Diabetes	28.1 (111)	24.7 (110)	0.258					
Obesity	59.5 (235)	40.6 (181)	<0.001					
Lung disease	7.1 (28)	10.5 (47)	0.080					
Baseline characteristics at time of hospital admission								
Days from symptoms onset to hospital admission#	7 (5 - 8)	6 (3 - 9)	0.0014†					

Hospitalized, requiring supplemental oxygen	95.2 (376)	93.5 (418)	0.355				
Hospitalized, receiving noninvasive mechanical ventilation or high-flow oxygen devices	0 (0)	0.7 (3)	0.252‡				
Oxygen saturation on room at cohort entry	92 (89 - 93)	90.5 (88 - 93)	0.0014†				
Respiratory frequency	20 (20 - 21)	20 (20 - 22)	0.3096†				
Heart rate	89 (80 - 100)	90 (78 - 102)	0.3703†				
Temperature	36.3 (36 - 37)	36.2 (36 - 36.9)	0.4612†				
NEWs							
Low	36.0 (142)	28.3 (126)					
Medium-low	19.8 (78)	19.3 (86)	0.006				
Medium	34.7 (137)	35.4 (158)					
High	9.6 (38)	17.0 (76)					
Concomitant medications prior to cohort admission							
ACE inhibitors / AIIRA	45.3 (179)	47.3 (211)	0.563				
NSAIDs	17.0 (67)	15.3 (68)	0.499				
Immunosuppressors	1.5 (6)	2.2 (10)	0.444				
Statins	8.9 (35)	8.1 (36)	0.681				
Ivermectin	6.3 (25)	3.4 (15)	0.044				
Anticoagulants	3.8 (15)	4.0 (18)	0.859				
Corticosteroids	8.6 (34)	11.0 (49)	0.248				

615 616

\*\* Data was missing from 20 patients in Control Group

All data are % (n), except for: # Data are in median (interquartile range  $_{25:75}$ )

All p values are for Chi2 except † for Wilcoxon rank-sum (Mann-Whitney) test, and ‡ for Fisher's exact test

618

619 **TABLE 1.** Demographic and clinical characteristics of the patients at baseline

	EPIC (N=395)	Control (N=446)	P value						
Concomitant medication during hospitalization									
None	0 (0)	0.7 (3)	0.252‡						
Corticoids	100 (395)	91 (406)	<0.001						
Heparin	99.2 (392)	91.9 (410)	<0.001						
Convalescent plasma	0 (0)	71.1 (317)	<0.001						
Monoclonal antibodies	0.3 (1)	0 (0)	0.470‡						
Antibiotics	69.4 (274)	72 (321)	0.407						
Ivermectin	0 (0)	0.2 (1)	1.000‡						
Tocilizumab	0 (0)	0.2 (1)	1.000‡						
Colchicine	0 (0)	0.2 (1)	1.000‡						
Remdesivir	0.3 (1)	0 (0)	0.470‡						
All data are % (n)									

All P values are for Chi2 except † for Wilcoxon rank-sum (Mann-Whitney) test, and ‡ for Fisher's exact test

	EPIC	Control	Estimator	Crude	IPTW†	Doubly robust
Outcomes	(N=395)	(N=446)				adjustment‡
Primary outcome						
			OR	0.68	0.66	0.65
				(95%CI 0.48-0.97)	(95%CI 0.46 -	(95%CI 0.44-0.98)
Overall mortality at day 28 since	15.7 (62)	21.5 (96)		p 0.031	0.96)	p 0.038
hospital admission					p 0.030	
			HR	0.72	0.70	0.72
				(95%CI 0.52 - 0.99)	(95%CI 0.50-0.98)	(95%CI 0.50-1.01)
				p 0.041	p 0.037	p 0.060
Secondary outcomes						
Overall mortality at day 21 since	14.9 (59)	19.3 (86)	OR	0.73	0.72	0.73
hospital admission				(95%CI 0.51 -	(95%CI 0.49 -	(95%CI 0.48 -
				1.05)	1.06)	1.10)
				p 0.094	p 0.093	p 0.127
Overall mortality at day 14 since	11.1 (44)	13.5 (60)	OR	0.80	0.81	0.86
hospital admission				(95%CI 0.53 -	(95%CI 0.52 -	(95%CI 0.53 -
				1.21)	1.26)	1.39)
				p 0.304	p 0.346	p 0.533
Status in WHO 6-points ordinal s	scale:		<u> </u>			
WHO 6-points ordinal scale at			Proportional	0.75	0.74	0.71
day 28			OR	(95%CI 0.55 -	(95%CI 0.54 -	(95%CI 0.50 - 1)
1 Full restitution	76.5 (302)	71.2 (31)		1.02)	1.03)	p 0.054
2 Incomplete restitution	2 (8)	4.5 (20)		p 0.07	p 0.071	
3 Hospitalized NO oxygen	1.3 (5)	0.4 (2)				
4 Hospitalized with oxygen	0.5 (2)	0.4 (2)				
5 Invasive ventilatory	4.1 (16)	1.8 (8)				
6 Death	15.7 (62)	21.5 (96)				
WHO 6-points ordinal scale at	<u> </u>		Proportional	0.79	0.79	0.75
day 21			OR	(95%CI 0.58 -	(95%CI 0.57 -	(95%CI 0.54 -
				1.06)	1.08)	1.06)
1 Full restitution	74.2 (293)	69.3 (31)		p 0.117	p 0.133	p 0.101

2 Incomplete restitution	2 (8)	3.6 (16)				
3 Hospitalized NO oxygen	1.3 (5)	0.2 (1)				
4 Hospitalized with oxygen	2.8 (11)	4.3 (19)				
5 Invasive ventilatory	4.8 (19)	3.1 (14)				
6 Death	14.9 (59)	19.3 (86)				
WHO 6-points ordinal scale at			Proportional	0.73	0.71 (95%CI 0.53	0.68 (95%CI 0.50
day 14			OR	(95%CI 0.55 -	- 0.95)	- 0.94)
				0.96)	p 0.021	p 0.019
1 Full restitution	68.6 (271)	60.3 (27)		p 0.026		
2 Incomplete restitution	2.3 (9)	2.7 (12)				
3 Hospitalized NO oxygen	2.3 (9)	2.5 (11)				
4 Hospitalized with oxygen	7.1 (28)	12.3 (55)				
5 Invasive ventilatory	8.6 (34)	8.5 (38)				
6 Death	11.1 (44)	13.5 (60)				
Proportion of adverse events	24.8 (98)	27.1 (121)	OR	0.86	0.82	0.81
				(95%CI 0.63 -	(95%CI 0.59 -	(95%CI 0.57 -
				1.18)	1.13)	1.16)
				p 0.349	p 0.227	p 0.257

630 All data are % (n), except for: #: Data are in median (interquartile range 25.75)

631 OR: odds ratio, HR: hazard ratio, sHR:sub-hazard ratio

632 †IPTW ‡Doubly robust adjustment

# **TABLE 3.** Clinical Outcomes in EPIC and control groups

	EPIC	Control						
	(N=395)	(N=446)						
Any patient with an adverse event	24.8 (98)	27.1 (121)						
Total of adverse events	145	168						
Туре								
Mild AE	1.8 (7)	0.2 (1)						
Moderate AE	2.3 (9)	1.6 (7)						
Severe AE	12.9 (51)	12.1 (54)						
Serious adverse events	19.7 (78)	23.8 (106)						
Relatedness								
Not related AE	35.2 (139)	NA						
Possible related AE	0.8 (3)	NA						
Probable related AE	0.8 (3)	NA						
Association								
Associated to concomitant disease	22 (87)	18.4 (82)						
Associated to concomitant medication	0.5 (2)	0						
Associated to COVID-19	33.4 (132)	35.6 (159)						

640 NA: Not applicable

641 **TABLE 4**. Review of safety outcomes



